Genentech Shows Off Positive Results From Phase III HEMLIBRA, TECENTRIQ Studies Post author:Sam Post published:November 19, 2017 Post category:BioPharma Data will be submitted to health authorities globally, including the FDA and EMA. Source: BioSpace You Might Also Like FDA Green Lights Gilead's Vosevi, With a Black Box Warning Attached July 18, 2017 AstraZeneca Continues to Divest Assets, Takes Stake in Mereo BioPharma With New Deal October 29, 2017 Bay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen's Neulasta June 11, 2017
AstraZeneca Continues to Divest Assets, Takes Stake in Mereo BioPharma With New Deal October 29, 2017
